Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats
Authors:
- Xinxia ZhuXZXinxia Zhu
- Russell PotterfieldRPRussell Potterfield
- Kenneth A. GruberKGKenneth A. Gruber
- Emma ZhangEZEmma Zhang
- Samuel D. NewtonSNSamuel D. Newton
- Mason A. NorgardMNMason A. Norgard
- Peter R. LevasseurPLPeter R. Levasseur
- Peng BaiPBPeng Bai
- Xu ChenXCXu Chen
- Qingyang GuQGQingyang Gu
- Aaron J. GrossbergAGAaron J. Grossberg
- Daniel L. MarksDMDaniel L. Marks
Open Access
- 7 November 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (1)
Abstract
Cancer patients undergoing chemotherapy often experience anorexia and weight loss that substantially deteriorates overall health, reduces treatment tolerance and quality of life, and worsens oncologic outcomes. There are currently few effective therapeutic options to mitigate these side effects. The central melanocortin system, which plays a pivotal role in regulating appetite and energy homeostasis, presents a logical target for treating anorexia and weight loss. In this preclinical study, we evaluated the efficacy of TCMCB07, a synthetic antagonist of the melanocortin-4 receptor, in mitigating anorexia and weight loss in several rat models of chemotherapy: cisplatin, 5-fluorouracil, cyclophosphamide, vincristine, doxorubicin, and a combination of irinotecan and 5-fluorouracil. Our results indicate that peripheral administration of TCMCB07 improved appetite, stabilized body weight, preserved fat and heart mass, and slightly protected lean mass after multiple cycles of chemotherapy. Furthermore, combining TCMCB07 with a growth differentiation factor 15 antibody enhanced treatment effectiveness. Similar effects from TCMCB07 treatment were observed in a rat tumor model following combination chemotherapy. No notable adverse effects nor increased chemotherapy-related toxicities were observed with TCMCB07 treatment. These findings suggest that peripheral administration of TCMCB07 holds promise as a therapeutic approach for alleviating chemotherapy-induced anorexia and weight loss, potentially benefiting numerous patients undergoing chemotherapy.Keywords
This publication has 73 references indexed in Scilit:
- Management of chemotherapy-induced side-effectsThe Lancet Oncology, 2005
- The Regulation of Feeding and Metabolic Rate and the Prevention of Murine Cancer Cachexia with a Small-Molecule Melanocortin-4 Receptor AntagonistEndocrinology, 2005
- Anatomy and regulation of the central melanocortin systemNature Neuroscience, 2005
- Genetic approaches to studying energy balance: perception and integrationNature Reviews Genetics, 2002
- Reversal of Cancer Anorexia by Blockade of Central Melanocortin Receptors in RatsEndocrinology, 2001
- Role of the central melanocortin system in cachexia.2001
- Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecanBritish Journal of Pharmacology, 2001
- Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.2000
- Role of melanocortinergic neurons in feeding and the agouti obesity syndromeNature, 1997
- Determination of subcutaneous tumor size in athymic (nude) miceCancer Chemotherapy and Pharmacology, 1989